Accelerating Biopharmaceutical CMC with NGS Technology through an AI-Driven and GMP-Compliant Digital Infrastructure

February 10, 2026

Biopharmaceutical manufacturing demands analytical methods to be comprehensive and sensitive to ensure product quality, consistency, and patient safety. Next-generation sequencing (NGS) provides broad characterization across multiple Critical Quality Attributes (CQAs), including genetic identity/integrity, vector confirmation, detection of impurities and adventitious agents. NGS is increasingly reflected in regulatory guidelines as a replacement for traditional in vivo testing. However, deploying and executing NGS assays across R&D and GMP environments, presents a challenge to maintain data integrity, traceability, and interoperability.

Genedata Selector^® addresses this gap with an end-to-end digital platform that integrates with ELN/LIMS and instrument ecosystems. It automates data capture and processing, standardizes data organization, assay execution, and reporting. By combining assay design, pipeline orchestration, QC dashboards, and audit-ready documentation, Genedata Selector streamlines tech transfer from R&D to GMP sites and provides the foundation for AI/ML across complex workflows. This unlocks faster assay optimization, consistent execution, and higher confidence in release decisions, supporting reliable and high-quality drug supply and improved patient safety.